The tweet was deleted by the author.
But we saved everything 🙂.
Spyre Therapeutics, Inc. will take part in the Leerink Partners Therapeutics Forum scheduled for July 14 in Boston, Massachusetts.
Company representatives plan to host investor meetings throughout the forum, aiming to engage with partners and stakeholders. The event serves as a significant opportunity for Spyre Therapeutics, Inc. to connect with the investment community and highlight its ongoing projects. Details about agenda specifics have not yet been disclosed.
View post on X Loading...
Spyre Therapeutics, Inc. previously reported strong Phase 2 data for its SPY002 program in ulcerative colitis, achieving a 10.7-point reduction in RHI score and 33 percent remission rates, according to company disclosures. The data release highlighted progress in the company’s development pipeline. Investors are likely to watch for additional updates on clinical milestones at the upcoming event.